Salvage therapy for complex bone and joint infections with ceftaroline: a multicentre, observational study

Malandain, D.; Dinh, Aurélien; Ferry, Tristan; Touchais, S.; Lustig, Sébastien; Laurent, François; Corvec, Stéphane; Bémer, Pascale; Asseray, Nathalie; Boutoille, David

doi:10.1016/j.ijantimicag.2017.05.021

Cited by 6 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the retrospective study performed by Malandain et al [27] using ceftaroline as a salvage therapy for complex bone and joint infections, 16 out of 19 enrolled patients had a polymicrobial infection and in 17 cases ceftaroline was co-administered with another antibiotic. Researchers reported a positive outcome at EOT in the 68% of patients and at 6 months follow-up in 37% of patients but we should notice that 6 months follow-up outcome has not been reported in 5/19 patients.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…Furthermore, an adjustment is indicated in ceftaroline dose if creatinine clearance (CrCL) is ≤ 50 mL/min. [33] As reported in table 1. twelve of the selected studies reported the utilization of the 600 mg q8 dose [12], [10], [14], [15], [18], [26], [27], [29], [31], [13] and three of the 800 mg q12 dose [16], [20], [26].…”

Section: Off Label Dosementioning

confidence: 99%

“…Also, Lalikian [29] reported 6 AEs, of these the 4,5-fold increase in AST and 13,7-fold increase in ALT levels in the only patient receiving ceftaroline TDD of 1800 mg after 19 days of therapy. Malandain [27] instead, reported the incidence of neutropenia requiring ceftaroline discontinuation in 2 patients, in one patient receiving the TDD of 1800 mg plus trimethoprim/sulfametoxazole, but also in one patient receiving the standard dose. In his work, Casapao [12] reported 13 AEs associated with off label dose (out of a total number of 41 reported AEs): diarrhea, constipation, hypokalemia, thrombocytopenia, chest pain, leukopenia reported in one patient each, rash and renal failure in three patients each.…”

Section: Off Label Dosementioning

confidence: 99%

See 2 more Smart Citations

Off-label use of ceftaroline fosamil: A systematic review

Pani

Colombo

Agnelli

et al. 2019

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Highlights  Ceftaroline fosamil is a fifth-generation cephalosporin with anti-MRSA activity, frequently prescribed off label in bacteremia, endocarditis, osteoarticular infections, hospital acquired pneumonia, meningitis  All studies included in this review show efficacy of the off-label use of ceftaroline (77% of clinical success), few adverse events are reported (9%) but not all included studies reported adverse events  Studies included in this review used different doses and dosing intervals, because of renal adjustment and because off-label use of higher doses which could reach higher pharmacodynamic targets in severe infections with better outcomes and a comparable safety profile  Quality of included study is low because of the retrospective nature of studies, case series and small sample sizes  Requirement of more structured evidences, RCT, PK/PD studies to assess real world efficacy and safety of ceftaroline in indications different from the approved

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Section: Off Label Dosementioning

confidence: 99%

Section: Off Label Dosementioning

confidence: 99%

See 1 more Smart Citation

Off-label use of ceftaroline fosamil: A systematic review

Pani

Colombo

Agnelli

et al. 2019

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

show abstract

“…Seven case series, 4 retrospective observational studies, 5 case-controls or retrospective matched cohorts, and 1 prospective, open-label study reported off-label use of ceftaroline. [35][36][37][38][43][44][45].…”

Section: Off-label Uses Of Ceftarolinementioning

confidence: 99%

“…Patients in these studies either received ceftaroline monotherapy or with another antibiotic with an overall clinical success rate of 87.3% (Table 1). [35][36][37][38][39][40][41][42] Information on concomitant use of other antibiotics with activities on MRSA was available for 80 patients with BJI. Twenty-two (27.5%) had at least one other antibiotic used concomitantly.…”

Section: Bone and Joint Infectionsmentioning

confidence: 99%

Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance

2022

View full text Add to dashboard Cite

Objective To assess the success rates of off-label uses of ceftaroline for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and evaluate emerging ceftaroline resistance. Data Sources We queried PubMed/MEDLINE, with the search term “Ceftaroline.” Articles were restricted to the English language and year of publication (January 1, 2009-January 31, 2022). Study Selection and Data Extraction Clinical trials, observational studies, and case reports that reported efficacy, safety, pharmacokinetics, use in MRSA infections other than acute bacterial skin infection and community-acquired pneumonia, and ceftaroline resistance were selected. Data Synthesis The search pooled 103 publications and all abstracts were reviewed. Forty-six articles that reported efficacy, safety, pharmacokinetics, or off-label use in multiple patients and 7 articles on ceftaroline resistance are used in this review. Ceftaroline has been approved for treatment of acute skin/soft tissue infection and community-acquired pneumonia. Ceftaroline’s efficacy in off-label infections ranged from 66.7% to 87.3% depending on the types of infection. There were 14 documented cases of ceftaroline resistance associated with PBP2a changes. Relevance to Patient Care and Clinical practice Case series and observational studies have documented success with ceftaroline alone or in combination with vancomycin or daptomycin for treatment of MRSA bone and joint, endovascular, diabetic foot infections, and bacteremia from other causes. Conclusion Despite the lack of randomized controlled trials, ceftaroline is used as salvage therapy for different MRSA infections. The data from case series and observational studies are promising but ceftaroline should be used judiciously as ceftaroline-resistant MRSA begin to emerge.

show abstract

Ceftaroline fosamil/cotrimoxazole

2017

Reactions Weekly

View full text Add to dashboard Cite

Salvage therapy for complex bone and joint infections with ceftaroline: a multicentre, observational study

Cited by 6 publications

References 5 publications

Off-label use of ceftaroline fosamil: A systematic review

Off-label use of ceftaroline fosamil: A systematic review

Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance

Ceftaroline fosamil/cotrimoxazole

Contact Info

Product

Resources

About